Shares in AOTI, Inc. (LSE:AOTI) edged higher on Wednesday, placing the wound-care medical technology group among the day's modest top gainers on London's junior market. The US-based, AIM-listed company has become one of the more closely watched names in the healthcare corner of the market this summer, largely on the strength of a regulatory development in its home market that could, over time, dramatically widen the pool of American patients able to access its therapy on insurance. AOTI specialises in Topical Wound Oxygen (TWO2) therapy for chronic wounds such as diabetic foot ulcers, a stubborn and costly clinical problem. For investors scanning the small-cap MedTech space, the combination of a differentiated product, double-digit Revenue growth and a potential step-change in US reimbursement has kept the shares firmly on the radar.
What Happened to AOTI Shares?
On 26 August 2026, AOTI shares rose 2.52% to trade at around 143p, valuing the company at roughly £147.84m. The move was a continuation of the firmer tone that has characterised the stock since late July rather than a response to any single fresh announcement on the day. No new regulatory news service (RNS) statement was published by the company on 26 August, so the gain is best read as ongoing momentum from developments earlier in the summer, alongside general sentiment towards the shares. Trading in AIM-quoted names of this size can be thin, and daily moves of a few percentage points are common in either direction. The more substantive catalysts sit in the company's July disclosures, which reset the Investment narrative around its long-term US opportunity.
Latest Company Developments
The standout event came on 24 July 2026, when AOTI described what it called a "transformational milestone". The US Centers for Medicare & Medicaid Services (CMS) issued a proposed Local Coverage Determination (LCD) affirming that topical oxygen therapy is reasonable and necessary for treating diabetic foot ulcers in Medicare enrollees. Crucially, this is a proposed determination, not a final one: it enters a 45-day public comment period, after which CMS is expected to finalise the LCD within a year. Once finalised, the company says the coverage would extend access to roughly 69 million Medicare beneficiaries. AOTI frames the current addressable market, where coverage already exists, at about $400m, and points to a far larger longer-term opportunity of around $26bn as coverage broadens across Medicaid and commercial payers. The company states it holds roughly 75% of the topical oxygen therapy market with TWO2. These figures are the company's own and depend on the LCD being finalised.
Financial Performance
AOTI's most recent numbers came in a trading statement on 27 July 2026, covering the first half of 2026. The company reported H1 revenue of approximately $35m, up around 10% year on year on a reported basis. Excluding the effect of Arizona Medicaid, underlying growth was stronger at about 18%. AOTI did not disclose H1 gross Margin or adjusted EBITDA in that update. On the balance sheet, cash and cash equivalents stood at approximately $13.8m at 30 June 2026, against net Debt of around $6.3m. For context, the full-year 2025 results published on 30 March 2026 showed revenue of $66.5m, up 14.0%, a gross margin of 87.5% (from 88.0% the prior year) and adjusted EBITDA of $7.5m, an 11.3% margin, down from $8.1m in 2024. Year-end 2025 cash was $13.4m, with net debt of about $6.5m. Notably, management said it believes it is unlikely the revenue growth trajectory will change materially until the Final LCD is in place.
The Growth Story
The bull case rests on TWO2 therapy and the trajectory of US reimbursement. Diabetic foot ulcers are a large and growing clinical burden, associated with high rates of hospitalisation and amputation, and AOTI points to clinical evidence supporting its cyclical topical oxygen approach. The immediate growth engine is expanding payer coverage across US Medicare, Medicaid and commercial plans. The proposed national CMS coverage determination is central to that story: if finalised, it would move topical oxygen from a therapy reimbursed in pockets of the country to one with a clear national pathway for Medicare's large elderly population. AOTI has also been building access beyond the United States, including a NICE fast-track recommendation flagged in September 2025, a place in an NHS Supply chain framework and market access in Germany. Since its 2024 London listing, the company has positioned that broadening reimbursement footprint as the route to converting strong clinical data into sustained revenue.
Risks Investors Should Watch
The risks are closely tied to the opportunity. Reimbursement dependence is the most obvious: the proposed LCD is not final, the comment period could produce changes, and the timeline stretches out to as much as a year. US healthcare policy more broadly can shift, and coverage decisions are outside the company's control. Execution and scaling matter too; if national coverage does arrive, AOTI must expand capacity and commercial reach to capture it, and management's own guidance implies growth may stay subdued until the Final LCD lands. The company remains reliant on a single core therapy, which concentrates risk, and it faces competition across the wider advanced wound-care market. The modest cash balance and net debt position leave limited headroom, and the large addressable-market figures cited are company estimates contingent on regulatory outcomes rather than guaranteed revenue.
What Could Drive the Shares Next?
The clearest potential catalyst is progress on the CMS Local Coverage Determination: the outcome of the comment period and, ultimately, a Final LCD would be a material event either way. AOTI's next scheduled financial update, its 2026 interim results, would give investors a fuller read on margins, EBITDA and cash burn to set against the H1 revenue print. Beyond that, further payer wins in the United States, additional international reimbursement progress and any commentary on capacity ahead of a possible coverage expansion could all shape sentiment. Given management's caution that growth may not change materially before the Final LCD, near-term newsflow on the regulatory timetable is likely to carry the most weight.
The Bottom Line
AOTI Inc (LSE:AOTI): AOTI's 2.52% rise on 26 August 2026 reflects continued interest in a small-cap medtech story that hinges on a single, potentially large regulatory decision. The verified fundamentals show a Business growing revenue at double-digit rates, high gross margins from its 2025 results and a modest cash position carrying some net debt. The proposed US Medicare coverage determination is a genuine milestone, but it remains a proposal, with a comment period and a finalisation window of up to a year, and the company's headline market-size figures are its own estimates. For now, AOTI sits in the category of a growth-and-reimbursement story where the biggest swing Factor lies ahead rather than behind. This article is for information only and does not constitute investment advice.






Please wait processing your request...